Compare iShares Gold Trust (IAU) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Novavax Inc — how do they compare? iShares Gold Trust trades at $78.86 (market cap $61.51B), while Novavax Inc trades at $12.79 (market cap $1.82B). The key difference: iShares Gold Trust is far larger — about 33.8× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and Novavax Inc for 59 Days on average.
| IAU | NVAX | |
|---|---|---|
Market Cap | $61.51B | $1.82B |
Volume | 3,206,729 | 6,198,505 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $12.56 |
52-Week Low | $74.21 | $6.22 |
Typical Hold Time | 49 Days | 59 Days |
Enterprise Value | — | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU stock trades at $78.88, up 2.36% with a $1.82 daily gain, though technical indicators show a bearish trend with 17 sell signals versus 2 buy signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, with support levels at $76-$77 and resistance at $78-$79. Recent news highlights gold's sensitivity to inflation data and interest rate expectations.
The outlook remains cautious due to macroeconomic headwinds and technical weakness. Investment opportunities exist if gold prices stabilize amid inflation concerns, but risks include persistent rate hikes and dollar strength. Monitor Fed policy and economic data for directional cues.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
